Literature DB >> 25976617

P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway.

Jiyi Xia1, Xiaolan Yu2, Li Tang3, Gang Li4, Tao He5.   

Abstract

Purinergic signaling has been implicated in the regulation of many cellular processes. A high concentration of ATP has been observed in the tumor microenvironment, suggesting a possible role of extracellular ATP in tumor progression. The P2X7 receptor, which belongs to the ligand-gated ion channel receptor family, is involved in tumor development and metastasis. In the present study, we found that extracellular ATP stimulated the invasion and migration of human T47D breast cancer cells, in a dose-dependent manner. BzATP (ATP analogue), but not ADP, also promoted invasion and migration. We further found that the P2X7 receptor was highly expressed in the T47D cells. After knockdown of the P2X7 receptor, ATP-stimulated invasion and migration were markedly inhibited. Moreover, activation of the P2X7 receptor by ATP downregulated the protein level of E-cadherin and upregulated the production of MMP-13. In addition, ATP time-dependently induced the activation of AKT via the P2X7 receptor, and the AKT pathway was required for the ATP-mediated invasion and migration. Taken together, our results revealed that activation of the P2X7 receptor by ATP promotes breast cancer cell invasion and migration, possibly via activation of the AKT pathway and regulation of E-cadherin and MMP-13 expression. Therefore, the P2X7 receptor may be a useful therapeutic target for the treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25976617     DOI: 10.3892/or.2015.3979

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  38 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 2.  Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT).

Authors:  A S Martínez-Ramírez; M Díaz-Muñoz; A Butanda-Ochoa; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2016-11-29       Impact factor: 3.765

3.  P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma.

Authors:  Hui Pan; Hongyan Ni; LeiLei Zhang; Yue Xing; Jiayan Fan; Peng Li; Tianyuan Li; Renbing Jia; Shengfang Ge; He Zhang; Xianqun Fan
Journal:  Tumour Biol       Date:  2016-07-28

Review 4.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 5.  Mechanosensitive Ion Channels: TRPV4 and P2X7 in Disseminating Cancer Cells.

Authors:  Jacob M Hope; Joshua D Greenlee; Michael R King
Journal:  Cancer J       Date:  2018 Mar/Apr       Impact factor: 3.360

6.  Purinoceptor expression in hepatocellular virus (HCV)-induced and non-HCV hepatocellular carcinoma: an insight into the proviral role of the P2X4 receptor.

Authors:  Madiha Khalid; Sobia Manzoor; Hassam Ahmad; Arun Asif; Tariq Ali Bangash; Amer Latif; Shahla Jaleel
Journal:  Mol Biol Rep       Date:  2018-10-20       Impact factor: 2.316

Review 7.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 8.  Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.

Authors:  Wen-Jun Zhang
Journal:  Purinergic Signal       Date:  2021-01-09       Impact factor: 3.765

Review 9.  P2X7 receptor: a critical regulator and potential target for breast cancer.

Authors:  Xiaodi Zhu; Qianqian Li; Wei Song; Xiaoxiang Peng; Ronglan Zhao
Journal:  J Mol Med (Berl)       Date:  2021-01-23       Impact factor: 4.599

Review 10.  To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Authors:  Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari
Journal:  Purinergic Signal       Date:  2021-08-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.